Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention

Ovarian Hyperstimulation Clinical Trial

Official title:
Comparison of Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention:Randomized Controlled Trial

Status Completed

Clinical Trial Summary

Giving oral Cabergoline or calcium infusion in women at high risk for developing ovarian hyperstimulation syndrome in context of assisted reproductive technologies aiming in its prevention

Clinical Trial Description

Women undergoing in vitro fertilization or intracytoplasmic sperm injection whom were at high risk for developing ovarian hyperstimuation syndrome were received either oral Cabergoline.5mg tablets for 7days starting on ovum pick up day and continued for 7days or received 10ml of 10%calcium gluconate in 200ml normal saline on ovum pick up day and continued for 4days ;

Study Design

Related Conditions & MeSH terms

Ovarian Hyperstimulation
Ovarian Hyperstimulation Syndrome

Clinical Trial Details

NCT number	NCT03473613
Study type	Interventional
Source	Benha University
Contact
Status	Completed
Phase	Phase 3
Start date	October 1, 2014
Completion date	April 15, 2017

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04002141` - Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis	Phase 2
Recruiting	`NCT02715336` - Efficacy and Safety of Medication Used to Stimulate Ovulation	Phase 4
Terminated	`NCT02975713` - Progesterone Diurnal Rhythm During Ovarian Stimulation for IVF	N/A
Completed	`NCT04175990` - IVF Outcome Following Progestogen Ovarian Stimulation	Phase 1
Not yet recruiting	`NCT02416596` - Routine Hysteroscopy in IVF/ICSI Cycles in Patients With Primary Unexplained Infertility	N/A